Physician profile
Randall Pierce
NPI 1659378867
$6,390.61
in general payments reported to CMS, 2019-2025
45 companies · $1,505 in 2025
The $1,505 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,361 · 2020: $334 · 2021: $271 · 2022: $737 · 2023: $1,064 · 2024: $1,119 · 2025: $1,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,847 · Food and Beverage: $1,608 · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,846.67 |
| Food and Beverage | $1,608.49 |
| Education | $232.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,532.74 | 2019-2025 | |
| Janssen Biotech, INC. | $365.79 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Seagen INC. | $329.38 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Amgen INC. | $282.30 | 2019-2023 | Lumakras |
| Pfizer INC. | $249.18 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $217.14 | 2019-2025 | Lynparza |
| Eisai INC. | $176.01 | 2019-2025 | |
| Daiichi Sankyo INC. | $166.66 | 2019-2025 | Enhertu, Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $161.20 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $154.94 | 2019-2022 | |
| Incyte Corporation | $142.60 | 2019-2023 | Jakafi |
| Merck Sharp & Dohme LLC | $138.45 | 2019-2024 | Keytruda |
| Genzyme Corporation | $137.71 | 2019-2024 | |
| Genentech USA, INC. | $116.77 | 2019 | |
| Celgene Corporation | $110.47 | 2019-2023 | Pomalyst |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $103.53 | 2022-2024 | Padcev |
| E.R. Squibb & Sons, L.L.C. | $103.25 | 2019-2025 | Opdivo |
| Lilly USA, LLC | $100.51 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Exelixis INC. | $74.41 | 2019-2025 | Cabometyx |
| Gilead Sciences, INC. | $73.73 | 2019-2024 | |
| Deciphera Pharmaceuticals INC. | $64.52 | 2023-2024 | Qinlock, Tgct |
| Verastem, INC. | $47.31 | 2019 | |
| Alexion Pharmaceuticals, INC. | $45.93 | 2020-2024 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $45.82 | 2022-2024 | Libtayo |
| Glaxosmithkline, LLC. | $44.59 | 2024-2025 | Ojjaara |
| Sobi, INC | $39.44 | 2022 | |
| Tersera Therapeutics LLC | $28.50 | 2019 | |
| Geron Corporation | $26.92 | 2024 | Rytelo |
| Genentech, INC. | $23.54 | 2024 | Phesgo, Tecentriq Hybreza |
| Beigene USA, INC. | $22.53 | 2024 | Brukinsa |
| Global Blood Therapeutics, INC. | $22.36 | 2022 | |
| Abbvie INC. | $20.87 | 2024 | |
| G1 Therapeutics, INC. | $20.57 | 2023 | Cosela |
| Portola Pharmaceuticals, LLC | $20.47 | 2020 | |
| Mirati Therapeutics, INC. | $19.67 | 2023 | Krazati |
| Karyopharm Therapeutics INC. | $19.01 | 2020 | |
| Array Biopharma INC | $18.25 | 2024 | Mektovi, Lorbrena, Braftovi |
| Taiho Oncology, INC. | $17.70 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $17.60 | 2024 | Onivyde |
| Tesaro, INC. | $16.96 | 2019 | |
| Partner Therapeutics, INC. | $16.88 | 2019 | |
| Sumitomo Pharma America, INC. | $15.44 | 2024 | Orgovyx |
| Takeda Pharmaceuticals U.S.A., INC. | $14.48 | 2019 | |
| Foundation Medicine, INC. | $13.38 | 2019 | |
| Clovis Oncology, INC. | $11.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.